|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Cilostazol for secondary stroke prevention:systematic review and meta-analysis显示文摘Background Stroke is one of the leading causes of death worldwide.Cilostazol,an antiplatelet and phosphodiesterase 3 inhibitor,has not been clearly established for ischaemic stroke use.We aim to determine the efficacy and safety of cilostazol for secondary stroke prevention.Methods MEDLINE,EMBASE,Cochrane Library,Web of Science and ClinicalTrials.gov were searched from inception to 25 September 2020,for randomised trials comparing the efficacy and safety of cilostazol monotherapy or dual therapy with another antiplatelet regimen or placebo,in patients with ischaemic stroke.Version 2 of the Cochrane risk-of-bias tool for randomised trials(RoB 2)was used to assess study quality.This meta-analysis was reported in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses(PRISMA)statement.Results Eighteen randomised trials comprising 11429 participants were included in this meta-analysis.Most trials possessed low risk of bias and were of low heterogeneity.Cilostazol significantly reduced the rate of ischaemic stroke recurrence(risk ratio,RR=0.69,95%CI 0.58 to 0.81),any stroke recurrence(RR=0.64,95%CI 0.54 to 0.74)and major adverse cardiovascular events(RR=0.67,95%CI 0.56 to 0.81).Cilostazol did not significantly decrease mortality(RR=0.90,95%CI 0.64 to 1.25)or increase the rate of good functional outcome(Modified Rankin Scale score of 0–1;RR=1.07,95%CI 0.95 to 1.19).Cilostazol demonstrated favourable safety profile,significantly reducing the risk of intracranial haemorrhage(RR=0.46,95%CI 0.31 to 0.68)and major haemorrhagic events(RR=0.49,95%CI 0.34 to 0.70).Conclusions Cilostazol demonstrated superior efficacy and safety profiles compared with traditional antiplatelet regimens such as aspirin and clopidogrel for secondary stroke prevention but does not appear to affect functional outcomes.Future randomised trials can be conducted outside East Asia,or compare cilostazol with a wider range of antiplatelet agents. | Choon Han Tan Andrew GR Wu Ching-Hui Sia Aloysius ST Leow Bernard PL Chan Vijay Kumar Sharma Leonard LL Yeo Benjamin YQ Tan | 2021 | Stroke & Vascular Neurology2021，6，3： | 2 |
| 2 | Targeted inhibition of STAT3 with a decoy oligonucleot ide abrogates head and neck cancer cell growth 显示文摘 | Leong PL Andrews GA Johnson DE | 2003 | Proc Natl Acad Sci USA2003，100，7： | 1 |
| 3 | Signals for nausea and emesis: Implications for models of upper gastrointestinal diseases 显示文摘 | Andrews PL Horn CC | 2006 | Auton Neurosci2006，125，12： | 1 |
| 4 | TNF receptor secretion after ex vivo adenoviral gene transfer to cornea and effect on in vivo graft survival显示文摘 | Sandra AR Frank PL Andrew JT | 2001 | Invest Ophthalmol Vis Sci2001，42，： | 1 |
| 5 | Costimulation blockade and tolerance显示文摘 | Andrew BA Christian PL Thomas CP | 2002 | Curr Opin Organ Transplanta- tion2002，7，1： | 1 |
| 6 | Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth显示文摘 | Leong PL Andrews GA Johnson DE | 2003 | Proc Natl Acad Sci USA2003，100，7： | 1 |
| 7 | Microscopic colitis-a com- mon cause of diarrhoea in older adults 显示文摘 | Williams JJ Beck PL Andrews CN | 2010 | Age Ageing2010，39，2： | 1 |
| 8 | Therapeutic aspects of fat embolism syndrome显示文摘 | Habashi NM Andrews PL Scalea TM | 2006 | Injury2006，37，4： | 1 |
| 9 | Therapeutic aspects of fat embolism syndrome 显示文摘 | Habashi NM Andrews PL Scalea TM | 2006 | Injury2006，37，4： | 1 |
| 10 | Targeted inhibition of STAT3 with a decoy oligonusleotide abrogates head and neck cancer cell growth显示文摘 | Leong PL Andrews GS Johnson DE | 2003 | Pro Natl Acad Sci USA2003，100，7： | 1 |
| 11 | Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth显示文摘 | Leong PL Andrews GA Johnson DE | 2003 | Proc Natl Acad Sci USA2003，100，7： | 1 |
| 12 | Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth显示文摘 | Leong PL Andrews GA Johnson DE | 2003 | Proc Natl Acad Sci USA2003，100，7： | 1 |
| 13 | Safety and dose escalating study of oral sodium phenylbutyrate in subjects with ALS显示文摘 | Cudkowicz ME Andrews PL Choudry R | 2007 | Neurology2007，68，1： | 1 |
| 14 | Target- ed-inhibition of STAT3 with adecoyoligo nucleotide abrogates head and neck cancer cell growth 显示文摘 | Leong PL Andrews GA Johnson DE | 2003 | Proc Natl Acad Sci USA2003，100，7： | 1 |
| 15 | Test-enhanced learning in medical ed- ucation 显示文摘 | Douglas PL Andrew CB Henry LR | 2008 | Medical Education2008，42，10： | 1 |
| 16 | Therapeutic aspects of fat embolism syndrome显示文摘 | Habashi NM Andrews PL Scalea TM | 2006 | Injury2006，37，4： | 1 |
| 17 | Targeted inhi- bition of Star3 with a decoy oligonucleotide abrogates head and neck cancer cell growth 显示文摘 | Leong PL Andrews GA Johnson DE | 2003 | Proc Natl Acad Sci USA2003，100，7： | 1 |
| 18 | Therapeutic aspects of fat embolism syndrome显示文摘 | Andrews PL Scalea TM | 2006 | Injury2006，374，： | 1 |
| 19 | Microscopic colitis-a common cause of diarrhoea in older adults 显示文摘 | Williams JJ Beck PL Andrews CN | 2010 | Age Ageing2010，39，2： | 1 |
| 20 | Division of Giardia larnblia osolates from humans into two genetically distinct assemblages by eleetrophoretic analysis of enzymes encoded at 27 loci and comparison with Giardia muris显示文摘 | Mayrhofer G Andrews RH Ey PL | 1995 | Parasitology1995，111，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员